| Issue Date | Title | Author(s) |
| Jan-2024 | Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific | Guo, Ye; Nakashima, Torahiko; Cho, Byoung Chul; Lim, Darren W. -T.; Yang, Muh-Hwa; Lou, Pei-Jen; Corry, June; Lin, Jin Ching; Zhu, Guo Pei; Kim, Kyung Hwan; Zhang, Bin; Li, Zhiming; Hong, Ruey-Long; Ng, Junice Yi Siu; Tan, Ee Min; Liu, Yan Ping; Stylianou, Con; Spiteri, Carmel; Porceddu, Sandro |
| 13-Sep-2024 | Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer | Cheng, Ying; Spigel, David R.; Cho, Byoung Chul; Laktionov, Konstantin K.; Fang, Jian; Chen, Yuanbin; Zenke, Yoshitaka; Lee, Ki Hyeong; Wang, Qiming; Navarro, Alejandro; Bernabe, Reyes; Buchmeier, Eva Lotte; Chang, John Wen-Cheng; Shiraishi, Yoshimasa; Goksu, Sema Sezgin; Badzio, Andrzej; Shi, Anhui; Daniel, Davey B.; Hoa, Nguyen Thi Thai; Zemanova, Milada; Mann, Helen; Gowda, Hema; Jiang, Haiyi; Senan, Suresh |
| 20-Jan-2024 | First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study. | Shah, Manish A.; Sun, Jong-Mu; Shen, Lin; Kato, Ken; Enzinger, Peter C.; Adenis, Antoine; Doi, Toshihiko; Kojima, Takashi; Li, Zhigang; Kim, Sung-Bae; Cho, Byoung Chul; Mansoor, Wasat; Li, Shau-Hsuan; Sunpaweravong, Patrapim; Maqueda, Maria Alsina; Buchschacher, Gary L.; Wu, Jimin; Shah, Sukrut; Bhagia, Pooja; Metges, Jean-Philippe |
| 1-Feb-2022 | First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-oflife results from the phase 3 KEYNOTE-590 study | Metges, Jean-Philippe; Kato, Ken; Sun, Jong-Mu; Shah, Manish A.; Enzinger, Peter C.; Adenis, Antoine; Doi, Toshihiko; Kojima, Takashi; Li, Zhigang; Kim, Sung-Bae; Cho, Byoung Chul; Mansoor, Wasat; Li, Shau-Hsuan; Sunpaweravong, Patrapim; Alsina, Maria; Buchschacher, Gary L.; Wu, Jimin; Shah, Sukrut; Bhagia, Pooja; Shen, Lin |
| 20-Jan-2021 | Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study. | Mansoor, Wasat; Kulkarni, Amit S.; Kato, Ken; Sun, Jong-Mu; Shah, Manish A.; Enzinger, Peter C.; Adenis, Antoine; Doi, Toshihiko; Kojima, Takashi; Metges, Jean-Philippe; Li Zhigang; Kim, Sung-Bae; Cho, Byoung Chul; Sunpaweravong, Patrapim; Alsina, Maria; Goekkurt, Eray; Suryawanshi, Shailaja; Norquist, Josephine; Shah, Sukrut; Shen Lin |
| 2019 | KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer | Kato, Ken; Shah, Manish A.; Enzinger, Peter; Bennouna, Jaafar; Shen, Lin; Adenis, Antoine; Sun, Jong-Mu; Cho, Byoung Chul; Ozguroglu, Mustafa; Kojima, Takashi; Kostorov, Vladimir; Hierro, Cinta; Zhu, Ying; McLean, Lee Anne; Shah, Sukrut; Doi, Toshihiko |
| Apr-2021 | KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma | Shah, Manish A.; Bennouna, Jaafar; Doi, Toshihiko; Shen, Lin; Kato, Ken; Adenis, Antoine; Mamon, Harvey J.; Moehler, Markus; Fu, Xiaolong; Cho, Byoung Chul; Bordia, Sonal; Bhagia, Pooja; Shih, Chie-Schin; Desai, Anjali; Enzinger, Peter |
| 28-Aug-2021 | Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study | Sun, Jong-Mu; Shen, Lin; Shah, Manish A.; Enzinger, Peter; Adenis, Antoine; Doi, Toshihiko; Kojima, Takashi; Metges, Jean-Philippe; Li, Zhigang; Kim, Sung-Bae; Cho, Byoung Chul; Mansoor, Wasat; Li, Shau-Hsuan; Sunpaweravong, Patrapim; Maqueda, Maria Alsina; Goekkurt, Eray; Hara, Hiroki; Antunes, Luis; Fountzilas, Christos; Tsuji, Akihito; Oliden, Victor Castro; Liu, Qi; Shah, Sukrut; Bhagia, Pooja; Kato, Ken |
